文献速递脑血管病外科神经重症

动脉内使用阿昔单抗治疗与脑动脉瘤栓塞相关的血栓栓塞并发症:伦敦安大略经验

Intra-Arterial Use of Abciximab in Thromboembolic Complications Associated with Cerebral Aneurysm Coiling: The London Ontario Experience.
PubMed 文献 · World Neurosurg · 2017-01-16

该研究回顾性分析动脉瘤栓塞术中发生血栓栓塞并发症并接受动脉内阿昔单抗治疗的14例患者,年龄48-76岁,3例男性,7例蛛网膜下腔出血。仅完全再通与临床改善相关,但仅4例(28.5%)达到完全再通;8例(57%)出现输注相关并发症。作者认为阿昔单抗再通效果欠佳,存在出血和动脉瘤再通风险。

要点

  • 14例栓塞术中血栓栓塞并发症患者接受动脉内阿昔单抗治疗,仅4例(28.5%)完全再通。
  • 13例(93%)部分或完全再通,但仅完全再通与临床改善相关。
  • 8例(57%)出现输注相关并发症,包括出血和动脉瘤再通。

核心结论

  • 使用阿昔单抗(Reopro)输注对动脉瘤栓塞过程中血栓形成所致血管闭塞的成功再通低于理想水平。
  • 阿昔单抗存在相关风险,包括出血和动脉瘤再通。

研究设计与样本

  • 从动脉瘤栓塞数据库中选取栓塞术中发生血栓并发症后接受动脉内阿昔单抗治疗的患者进行分析。
  • 共14例栓塞患者发生血栓栓塞并发症并接受动脉内阿昔单抗输注,纳入进一步分析。

主要发现

  • 患者年龄范围48-76岁,3例为男性,7例有蛛网膜下腔出血。
  • 仅完全再通与临床改善相关,但仅4例(28.5%)出现完全再通。
  • 部分或完全再通发生于13例(93%)。
  • 8例(57%)出现输注相关并发症:3例动脉瘤再通,3例血栓远端迁移,1例出血并发症。
  • 8例出现与闭塞血管相关的急性梗死,而7例获得良好功能恢复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Experience with intra-arterial infusion of abciximab for the treatment of endovascular thrombotic complications is limited to short case series. Our objective is to evaluate the safety and effectiveness of this drug for the treatment of thromboembolic complications during aneurysm coiling and to determine the risk factors. METHODS: From an aneurysm coiling database, patients treated with intra-arterial abciximab after having thrombotic complications during the coiling procedure were selected for analysis. Complications after using abciximab were categorized as hemorrhage, distal migration of the thrombus, and aneurysm recanalization. RESULTS: Fourteen coiling patients sustained a thromboembolic complication and were treated using intra-arterial infusion of abciximab and were subjected to further analysis. The age range was 48-76 years. Three patients were male. Seven patients had subarachnoid hemorrhage. Only complete recanalization was associated with clinical improvement, but this occurred in only 4 patients (28.5%). Partial or complete recanalization occurred in 13 patients (93%). Eight patients (57%) had complications derived from the infusion. Three patients had aneurysm recanalization, 3 patients had distal migration of the thrombus and 1 patient had a hemorrhagic complication. Eight patients demonstrated acute infarcts related to the occluded vessel, whereas 7 patients made a good functional recovery. CONCLUSION: Successful recanalization of a vessel occluded by thrombus formation during aneurysm coiling using abciximab (Reopro) infusion is less than optimal. There are risks related to abciximab, including bleeding and aneurysm recanalization.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Martínez-Pérez R, Lownie SP, Pelz D, et al. Intra-Arterial Use of Abciximab in Thromboembolic Complications Associated with Cerebral Aneurysm Coiling: The London Ontario Experience. World Neurosurg. 2017. PMID: 28104522. doi:10.1016/j.wneu.2017.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。